This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Concert Pharmaceuticals マネジメント

マネジメント基準チェック /24

主要情報

Roger Tung

最高経営責任者

US$3.5m

報酬総額

CEO給与比率	17.0%
CEO在任期間	16.9yrs
CEOの所有権	1.4%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	16.3yrs

経営陣の近況

Recent updates

Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

Jan 22

Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Jan 11

Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Aug 27

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

May 25

Concert Pharma EPS beats by $0.02

May 04

Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Feb 27

Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia

Feb 01

Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Jan 23

How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

Dec 19

A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Nov 23

Concert Pharma EPS beats by $0.15

Nov 05

Concert Pharma launches late-stage study of CTP-543 in hair loss disorder

Nov 03

CEO報酬分析

Concert Pharmaceuticals の収益と比較して、Roger Tung の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2022	n/a	n/a	-US$127m
Jun 30 2022	n/a	n/a	-US$125m
Mar 31 2022	n/a	n/a	-US$95m
Dec 31 2021	US$4m	US$599k	-US$80m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$59m
Mar 31 2021	n/a	n/a	-US$77m
Dec 31 2020	US$3m	US$582k	-US$75m
Sep 30 2020	n/a	n/a	-US$73m
Jun 30 2020	n/a	n/a	-US$71m
Mar 31 2020	n/a	n/a	-US$77m
Dec 31 2019	US$3m	US$562k	-US$78m
Sep 30 2019	n/a	n/a	-US$79m
Jun 30 2019	n/a	n/a	-US$79m
Mar 31 2019	n/a	n/a	-US$73m
Dec 31 2018	US$5m	US$536k	-US$56m
Sep 30 2018	n/a	n/a	-US$41m
Jun 30 2018	n/a	n/a	US$104m
Mar 31 2018	n/a	n/a	US$104m
Dec 31 2017	US$3m	US$517k	US$95m
Sep 30 2017	n/a	n/a	US$89m
Jun 30 2017	n/a	n/a	-US$50m
Mar 31 2017	n/a	n/a	-US$50m
Dec 31 2016	US$3m	US$500k	-US$51m

報酬と市場: Roger's total compensation ($USD3.53M) is above average for companies of similar size in the US market ($USD2.48M).

報酬と収益: Roger's compensation has increased whilst the company is unprofitable.

CEO（最高経営責任者

Roger Tung (62 yo)

16.9yrs

在職期間

US$3,526,782

報酬

Dr. Roger D. Tung, Ph D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Richard Aldrich	Co-Founder & Independent Chairman of the Board	16.8yrs	US$129.05k	0.89% $ 4.6m
Roger Tung	Co-Founder	16.9yrs	US$3.53m	1.37% $ 7.1m
Marc Becker	Chief Financial Officer	5.2yrs	US$1.38m	0.20% $ 1.0m
James Cassella	Chief Development Officer	8.1yrs	US$1.51m	0.13% $ 674.6k
Nancy Stuart	Chief Operating Officer	15.4yrs	US$1.58m	0.27% $ 1.4m
Justine Koenigsberg	Senior Vice President of Corporate Communications & Investor Relations	no data	データなし	データなし
Jeffrey Munsie	Chief Legal Officer & Corporate Secretary	3.5yrs	データなし	0.062% $ 321.0k
Nabil Uddin	Vice President of Corporate Development	1.2yrs	データなし	データなし
Kimberly Mack	Vice President of Human Resources	less than a year	データなし	データなし
Christine Boisclair	Senior Vice President of Regulatory Affairs & Quality Assurance	1.2yrs	データなし	データなし

4.3yrs

平均在職期間

63yo

平均年齢

経験豊富な経営陣: CNCE's management team is considered experienced (4.3 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Richard Aldrich	Co-Founder & Independent Chairman of the Board	16.8yrs	US$129.05k	0.89% $ 4.6m
Roger Tung	Co-Founder	16.9yrs	US$3.53m	1.37% $ 7.1m
Christine van Heek	Independent Director	6.9yrs	US$99.05k	0.041% $ 214.7k
Peter Hutt	Independent Director	16.3yrs	US$94.05k	0.021% $ 109.6k
Wilfred Jaeger	Independent Director	16.8yrs	US$106.55k	0% $ 0
Jesper Hoiland	Independent Director	3.9yrs	US$96.55k	0.0082% $ 42.9k
Thomas Auchincloss	Independent Director	8.3yrs	US$109.05k	0.028% $ 147.5k

16.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: CNCE's board of directors are seasoned and experienced ( 16.3 years average tenure).

This company has been acquired

Concert Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Co-Founder notifies of intention to sell stock

Insufficient new directors

Insufficient new directors

Concert Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Concert Pharmaceuticals, Inc. Announces Not Stand for Re-Election of Ronald W. Barrett as Independent Director

Co-Founder notifies of intention to sell stock

Recent updates

Concert Pharmaceuticals, Inc. Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?

Price target decreased to US$13.67

Co-Founder notifies of intention to sell stock

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib Thrive-Aa1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Concert Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress

CinCor Pharma hits 52-week high on data for antihypertensive agent

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for Second CTP-543 Phase 3 Clinical Trial in Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target increased to US$14.10

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell Microcap Value Index

Concert Pharmaceuticals: A Balanced Risk/Reward

Concert Pharmaceuticals, Inc. Announces the Publication of Safety and Efficacy Data from the Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Phase 2 Clinical Trial for CTP-543

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug

Concert Pharmaceuticals, Inc. Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Concert Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Consensus revenue estimates fall by 60%

Full year 2021 earnings: EPS exceeds analyst expectations

Concert Pharmaceuticals, Inc. Announces Phase 3 Trials for Moderate to Severe Alopecia Areata

Concert Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Concert Pharmaceuticals, Inc. Announces Not Stand for Re-Election of Ronald W. Barrett as Independent Director

Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans

Concert Pharmaceuticals, Inc. Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Co-Founder notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.78 loss per share (vs US$0.60 loss in 3Q 2020)

Price target decreased to US$13.00

Price target decreased to US$14.17

Price target decreased to US$14.67

Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.41 loss in 2Q 2020)

Consensus revenue estimates increase to US$32.0m

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Concert Pharmaceuticals, Inc.(NasdaqGM:CNCE) dropped from Russell 3000E Value Index

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate

Consensus revenue estimates fall to US$1.80m

First quarter 2021 earnings released: US$0.67 loss per share (vs US$0.70 loss in 1Q 2020)

Concert Pharmaceuticals Reports CTP-543 Phase 3 Program for Alopecia Areata Advancing as Planned to Support NDA Filing in Early 2023

Concert Pharma EPS beats by $0.02

Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: US$2.40 loss per share (vs US$3.29 loss in FY 2019)

Concert Pharmaceuticals, Inc. Provides Update on Clinical Programs

New 90-day low: US$6.85

Co-Founder notifies of intention to sell stock

Concert Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021

Concert Pharmaceuticals, Inc. Announces Results from CTP-692 Phase 2 Trial in Patients with Schizophrenia

New 90-day low: US$7.51

Price target lowered to US$19.14

Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia

Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation

New 90-day high: US$13.07

How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?

New 90-day high: US$12.53

A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns

Analysts increase revenue estimates to US$6.32m

Earnings miss expectations

Third quarter 2020 earnings released: US$0.60 loss per share

Concert Pharma EPS beats by $0.15

Concert Pharmaceuticals Initiates THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

Concert Pharma launches late-stage study of CTP-543 in hair loss disorder

マネジメント基準チェック /24